<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03805022</url>
  </required_header>
  <id_info>
    <org_study_id>IB 2017-04</org_study_id>
    <secondary_id>2018-000186-36</secondary_id>
    <nct_id>NCT03805022</nct_id>
  </id_info>
  <brief_title>Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas</brief_title>
  <acronym>CIRSARC</acronym>
  <official_title>Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharma France</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate whether the addition of 3 additional
      neo-adjuvant cycles of chemotherapy (doxorubicin and ifosfamide) to standard management
      according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin and ifosfamide
      based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC
      patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic
      progression-free survival (M-PFS, after 3 years of follow-up).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For high-risk CINSARC patients, this is a multicenter randomized two-arm phase III trial,
      with a ratio 1:1:

        -  Arm A: standard management (3 cycles of neoadjuvant doxorubicin and ifosfamide based
           chemotherapy + surgery +/- radiotherapy)

        -  Arm B: experimental arm (6 cycles of neoadjuvant doxorubicin and ifosfamide based
           chemotherapy + surgery +/- radiotherapy)

      For low-risk CINSARC patients, this a multicenter prospective cohort with treatment at the
      discretion of the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multicenter trial with:
An open randomized two-arm phase III trial for high-risk CINSARC patients assessing whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin and ifosfamide) to standard management (3 cycles of neoadjuvant anthracycline and ifosfamide based chemotherapy + surgery +/- radiotherapy) improves the outcome of patients
a prospective cohort for low-risk CINSARC patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis progression-free survival in High-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Metastasis progression-free survival (M-PFS) defined as the time interval between the date of randomization and the date of death or distant progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Loco-regional relapse-free survival in High-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Loco-regional relapse-free survival (LR-RFS) defined as the time interval between the randomization date and the date of death or loco-regional progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in High-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival (PFS) defined as the time interval between the randomization date and the date of death or progression (as per RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in High-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival (OS) defined as the time interval between the randomization date and the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response in High-risk CINSARC patients</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
    <description>Best overall response under treatment as per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response in High-risk CINSARC patients</measure>
    <time_frame>An average of 6 months</time_frame>
    <description>Histological response defined as the proportion of recognizable cells on the tumor sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile in High-risk CINSARC patients</measure>
    <time_frame>Throughout the treatment period, an average of 6 months</time_frame>
    <description>Toxicity graded using the common toxicity criteria from the NCI v5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in Low-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival defined as the time interval between the randomization date and the date of death or progression (as per RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis progression-free survival in Low-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Metastasis progression-free survival defined as the time interval between the inclusion date and the date of death or distant progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional progression-free survival in Low-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Description of the treatment efficacy in terms of 3-years loco-regional progression-free survival defined as the time interval between the randomization date and the date of death or loco-regional progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in Low-risk CINSARC patients</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival defined as the time interval between the inclusion date and the date of death.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">334</enrollment>
  <condition>Non-metastatic Soft-tissue Sarcoma</condition>
  <condition>Resectable</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control-Arm phase III high-risk CINSARC:
Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 3 cycles in neoadjuvant setting.
Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental-Arm phase III high-risk CINSARC:
Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 6 cycles in neoadjuvant setting.
Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated at the discretion of the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60-75mg/m² day or 20-25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF), repeated every 3 weeks, up to 3 cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60-75mg/m² day or 20-25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF), repeated every 3 weeks, up to 6 cycles.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>At the discretion of the investigator</intervention_name>
    <description>Drug at the discretion of the investigator.</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          1. Histologically confirmed soft-tissue sarcoma by the RRePS (Réseau de Référence en
             Pathologie des Sarcomes et des Viscères) network, as recommended by the French NCI,

          2. Grade 2 or 3 according to the FNCLCC grading system,

          3. Available archived tumour sample for research purpose,

          4. Non-metastatic and resectable disease,

          5. No prior treatment for the disease under study,

          6. Age ≥ 18 years,

          7. Life expectancy ≥ 3 months,

          8. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1,

          9. Patients must have measurable disease (lesion in previously irradiated field can be
             considered as measurable if progressive at inclusion according to RECIST 1.1) defined
             as per RECIST v1.1 with at least one lesion that can be measured in at least one
             dimension (longest diameter to be recorded) as ≥ 10 mm or ≥ 15mm in case of
             adenopathy,

         10. Women of childbearing potential must have a negative serum pregnancy test before study
             entry. Both women and men must agree to use a medically acceptable method of
             contraception throughout the treatment period and for one year after discontinuation
             of treatment. Acceptable methods of contraception include intrauterine device (IUD),
             oral contraceptive, subdermal implant and double barrier. Subjects of childbearing
             potential are those who have not been surgically sterilized (e.g., vasectomy for males
             and hysterectomy for females) or have not been free from menses for ≥ 1 year,

         11. Voluntarily signed and dated written informed consents prior to any study specific
             procedure,

         12. Patients with a social security in compliance with the French law.

        Exclusion Criteria :

          1. Soft-tissue sarcoma with the following histological subtypes: well-differentiated
             liposarcoma, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clearcell
             sarcoma, embryonal and alveolar rhabdomyosarcoma,

          2. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except
             for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell
             carcinoma, or in situ transitional bladder cell carcinoma,

          3. Any other contraindication to anthracycline and Ifosfamide-based chemotherapy,

          4. Participation to a study involving a medical or therapeutic intervention in the last
             28 days,

          5. Known infection with HIV, hepatitis B, or hepatitis C,

          6. Females who are pregnant or breast-feeding,

          7. Other medical conditions may interfere with the conduct of the study and, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study,

          8. Individuals deprived of liberty or placed under legal guardianship,

          9. Unwillingness or inability to comply with the study protocol for any reason.

        Additional criteria for randomization :

          1. High-risk CINSARC signature,

          2. No more than one cycle of neo-adjuvant anthracycline-based chemotherapy before
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antoine ITALIANO, MD, PhD</last_name>
    <phone>+33 5.56.33.33.33</phone>
    <email>a.italiano@bordeaux.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone MATHOULIN-PELISSIER, MD, PhD</last_name>
    <email>m.mathoulin@bordeaux.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, MD, PhD</last_name>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine ITALIANO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas ISAMBERT</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas ISAMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie LEBRUN-LY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Valérie LEBRUN-LY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François BERTUCCI, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>François BERTUCCI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitut du Cancer</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly FIRMIN, MD</last_name>
      <email>nelly.firmin@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Nelly FIRMIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU</last_name>
      <email>chevreau.christine@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Christine CHEVREAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel LE CESNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Axel LE CESNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Phase III trial</keyword>
  <keyword>Soft-tissue sarcoma</keyword>
  <keyword>Resectable</keyword>
  <keyword>Non-metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

